Neurotech Pharmaceuticals, Inc. is a privately held biotechnology company focused on the development of transformative therapies for chronic eye diseases. Neurotech is a wholly-owned subsidiary of Neurotech Holdings, LLC and based in Cumberland, Rhode Island.
Our ECT Technology
Neurotech’s patented core technology platform, Encapsulated Cell Therapy (ECT), is a first-in-class, novel, versatile drug delivery platform in development for the treatment of a broad array of eye diseases. ECT is a genetically engineered ocular implant that enables continuous production of therapeutic proteins to the eye for at least 2 years.
Our ECT Candidates
Neurotech is exploring several candidates for the ECT platform. These include therapies for the treatment of macular telangiectasia (MacTel) and glaucoma (NT-501) and potential single or combination therapies for retinal degenerative disorders.